A Phase 1, First in Human, Dose-Escalation Study of UCT-03-008 in Participants With Advanced Solid Tumors
Latest Information Update: 14 Mar 2024
At a glance
- Drugs UCT-03-008 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors 1200 Pharma
Most Recent Events
- 27 Jan 2022 Status changed from not yet recruiting to recruiting.
- 11 Nov 2021 New trial record